ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2278

Pregnancy in Connective Tissue Diseases: A 30 Year Follow-up Study of 465 Pregnancies from a Spanish Monocentric Registry

Cristiana Sieiro Santos1, Paula Pérez García2, Jose Ordas Martínez2, Clara Moriano2, Carolina Álvarez Castro2 and Elvira Díez Álvarez2, 1Complejo Asistencial Universitario de León, León, Spain, 2CAULE, León, Spain

Meeting: ACR Convergence 2023

Keywords: autoimmune diseases, pregnancy

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 14, 2023

Title: (2257–2325) SLE – Diagnosis, Manifestations, & Outcomes Poster III

Session Type: Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Pregnancy in patients with connective tissue diseases are known to be at high risk for the occurrence of adverse pregnancy outcomes. We aim toevaluate the pregnancy outcomes in patients with systemic autoimmune diseases, including systemic lupus erythematosus (SLE), systemic sclerosis (SSc), primary Sjögren’s syndrome (pSS) and undifferentiated connective tissue disease (UCTD).

Methods: A retrospective and descriptive study was conducted from 1990 to 2020. All data were collected from the medical records of childbearing age women with SLE, SSc, SS and UTCD enrolled in our clinic at the time of their pregnancy and childbirth. The obstetric, maternal and fetal outcomes were collected and compared regarding diagnosis and adverse outcomes.

Results: The study group included 295 patients, 125 patients (42%) with SLE, 50 patients (17%) with SSc, 80 patients (27%) with Sjogren’s, 40 patients (14%) with UCTD.A total of 465 pregnancies were registered. The maternal and fetal outcomes are detailed in table 1 and figure 1. The mean age at delivery was 31.5±8.5 years and the mean duration of disease was 7.2±5.6 years. Pregnancy loss occurred in 21% of patients, live births in 66% of pregnancies, preterm delivery in 8%, postpartum haemorrhage in 6%, preeclampsia in 5%, placental abnormalities in 4%, ectopic pregnancy in 3%, premature rupture of membranes in 2%.Treatment with HCQ was received in 115 pregnancies in SLE (59%), 21 pregnancies in SSc (24%) 62 pregnancies in pSS (52%) and 32 pregnancies in UCTD (49%). Exposure to corticosteroids and biologics during pregnancy was 23 (18.4%), 6 (12%), 15 (19%) and 3 (7.5%), respectively. Patients with SLE had a higher risk of fetal morbidity, including abortion (p=0.03), mean abortion rate (p=0.03), preeclampsia (p=0.04), ectopic pregnancy (p=0.03), preterm delivery (p=0.02) and postpartum haemorrhage (p=0.01) than patients without SLE. The multivariate model adjusted for age, nulliparity, active disease activity during pregnancy, smoking and exposure to biologics, HCQ and corticosteroids found an association between unfavourable pregnancy outcomes and disease activity (OR 2.4 95% CI (1.3-7.2), p 0.003), whilst HCQ during pregnancy (OR 0.23 95% CI (0.03-0.82) had a protective effect.

Conclusion: 66% of pregnancies in patients with autoimmune diseases resulted in live births. Patients with SLE had higher rates of fetal and maternal morbidity than SSc, pSS and UCTD. Disease activity was associated with unfavourable pregnancy outcomes. Exposure to HCQ had a protective effect during pregnancy. Pregnancy planning and counselling prior to conception of patients with connective tissue diseases leads to a reduction in maternal and perinatal complications.

Supporting image 1

Supporting image 2


Disclosures: C. Sieiro Santos: None; P. Pérez García: None; J. Ordas Martínez: None; C. Moriano: None; C. Álvarez Castro: None; E. Díez Álvarez: None.

To cite this abstract in AMA style:

Sieiro Santos C, Pérez García P, Ordas Martínez J, Moriano C, Álvarez Castro C, Díez Álvarez E. Pregnancy in Connective Tissue Diseases: A 30 Year Follow-up Study of 465 Pregnancies from a Spanish Monocentric Registry [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/pregnancy-in-connective-tissue-diseases-a-30-year-follow-up-study-of-465-pregnancies-from-a-spanish-monocentric-registry/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/pregnancy-in-connective-tissue-diseases-a-30-year-follow-up-study-of-465-pregnancies-from-a-spanish-monocentric-registry/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology